The short interest data are out for the most recent settlement date, May 15. Generally speaking, companies within the biotech industry are considered to be a riskier group of stocks, with big potential upside and big potential downside.
As we have said before, FDA rulings can make or break the biotech stocks, and short sellers and mega-bulls often go to war against each other in these companies.....More>>>
A wild and woolly week gave investors more of a roller-coaster ride than we have seen in some time. Toss a big sell-off in with a terror attack in London, and worries over the health care bill in its current form, and you had all of the ingredients for a spike in volatility. While the insider selling slowed somewhat, top executives are still taking the chance to sell shares before the windows for....More>>>
You can not change a tiger into a kitten by stroking it.” – Franklin Delano Roosevelt
Today, we look at a name that has a presentation at the 21st Annual Meeting The American Society of Gene and Cell Therapy that’s taking place in Chicago from Wednesday through Saturday this week. Positive data could continue to be a catalyst for the stock. Investors seem to be anticipating....More>>>
The breakthrough therapy designation is generally bestowed upon some of the most innovative and potentially groundbreaking drugs in the pharmaceutical space. Trevena (NASDAQ:TRVN) is not much different with a potentially differentiated Phase III candidate called Oliceridine, which could be a wonderful therapy for the treatment of acute pain. Although the treatment is scientifically compelling, I....More>>>
Before explaining and updating my version of the Celgene (NASDAQ:CELG) story, first, I’ll briefly explain and link to the 2 1/2-year story of my bullish-bearish-bullish evolution of views on this stock. This will help lay the groundwork to why I am again accentuating the positives, understanding there are negatives; the article goes into both sides of the CELG argument.